Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection
Status:
Completed
Trial end date:
2020-10-05
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the activity of low dose oral selinexor
(KPT-330) and to evaluate the clinical recovery, the viral load, length of hospitalization
and the rate of morbidity and mortality in participants with severe COVID-19 compared to
placebo. The study had 2 arms and evaluated selinexor 20 mg + standard of care (SoC) and
placebo + SoC. As the treatment for COVID-19 is rapidly evolving, the SoC varied over time
and across regions of the world.